T1	Participants 153 184	tumors of hematopoietic organs.
T2	Participants 435 479	patients with tumors of hematopoietic organs
T3	Participants 669 727	multiple institutions using a central registration system.
T4	Participants 865 872	(55/93)
T5	Participants 912 919	(44/93)
